Every 10-Q that Atossa Therapeutics, Inc. (ATOS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ATOS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATOS filings page.
Atossa Therapeutics, Inc. reported a net loss of $8.5 million for the quarter ended June 30, 2026, or $0.95 per share, as it continues clinical development of its lead drug candidate (Z)-endoxifen. For the first six months of 2026, net loss was $18.1 million, up from $15.1 million a year earlier, mainly due to higher general and administrative expenses tied to legal and intellectual-property matters, while research and development spending was roughly flat.
Cash and cash equivalents were $26.1 million as of June 30, 2026, down from $41.3 million at year-end after $19.2 million of operating cash outflows over six months. Management states these conditions raise substantial doubt about the company’s ability to continue as a going concern and expects existing resources will likely be insufficient to fund planned operations for the next twelve months without additional capital. In June 2026 Atossa completed a registered direct offering of 1,363,637 common shares with accompanying warrants, generating $4.0 million of net proceeds, and also began using a $50.0 million at-the-market facility. The company remains a pre-revenue, clinical-stage business advancing multiple Phase 2 (Z)-endoxifen trials and pursuing regulatory designations in oncology and rare diseases.
Atossa Therapeutics, Inc. reported a larger net loss of $9.6M for the quarter ended March 31, 2026, with no revenue as it remains a clinical-stage company focused on (Z)-endoxifen programs in oncology and rare diseases. Operating expenses rose to $9.9M, driven mainly by higher clinical trial spending and legal fees tied to patent matters. Cash, cash equivalents and restricted cash fell to $31.8M, and management disclosed working capital of $29.2M and ongoing negative cash flows, stating that these conditions raise substantial doubt about the company’s ability to continue as a going concern. Atossa put in place a new at-the-market equity program of up to $50M, effected a 1-for-15 reverse stock split, and highlighted FDA Rare Pediatric Disease and orphan designations for (Z)-endoxifen in Duchenne muscular dystrophy and McCune‑Albright Syndrome.
Atossa Therapeutics (ATOS) reported Q3 2025 results showing a net loss of $8.7M (loss per share $0.07) as the company advanced its (Z)-endoxifen programs. Operating expenses were $9.3M, driven by R&D of $5.4M (up 57% year over year) and G&A of $3.9M (up 31%). Interest income was $0.6M.
For the nine months, net loss was $23.8M and cash used in operations was $19.2M. Cash and cash equivalents totaled $51.8M with working capital of $47.5M, and management believes cash funds operations for at least one year. The company maintains an at-the-market facility of up to $100.0M with no sales during 2025 to date. Following warrant expirations, no warrants were outstanding at September 30, 2025.
As of November 1, 2025, shares outstanding were 129,171,424; this is a baseline figure, not the amount being offered. ATOS received PTAB institution decisions on two patent challenges, with responses due by January 26, 2026. Nasdaq is monitoring minimum bid price compliance after an additional review period.
Atossa Therapeutics reported widening losses as it advances clinical programs for its lead candidate, oral (Z)-endoxifen. For the six months ended June 30, 2025 the company recorded a $15.1 million net loss and used $13.2 million of cash in operations, compared with $11.9 million and $9.2 million a year earlier. Cash and cash equivalents totaled $57.9 million at June 30, 2025, with working capital of $55.7 million, and management expects this cash to fund operations for at least one year. Total operating expenses rose to $16.5 million for the six-month period driven by higher R&D spending on (Z)-endoxifen trials.
The company highlighted positive clinical signals: low-dose (Z)-endoxifen reduced mammographic breast density (1 mg: 17.3%, 2 mg: 23.5%, both p<0.01) and neoadjuvant and I-SPY 2 data showed tumor suppression and tolerability. Material items to monitor include pending PTAB proceedings challenging two patents (petitions filed by Intas), a non-cancellable clinical commitment of $7.9 million, and a Nasdaq notice requiring the company to regain a $1.00 bid compliance by August 20, 2025.